

Variant: NM_000546.6(TP53):c.1010G>C (p.Arg337Pro)

Version: 1.0

CA000014 [↗](#)

177879 (ClinVar) [↗](#)

Gene: TP53 ([HGNC:7157](#))

Condition: Li-Fraumeni syndrome ([MONDO:0018875](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: a4a36153-1d09-4853-abdd-c07a6341e1fb

Approved on: 2025-05-07

Published on: 2025-07-18

HGVS expressions

NM_000546.6:c.1010G>C

NM_000546.6(TP53):c.1010G>C (p.Arg337Pro)

NC_000017.11:g.7670699C>G

CM000679.2:g.7670699C>G

NC_000017.10:g.7574017C>G

CM000679.1:g.7574017C>G

NC_000017.9:g.7514742C>G

NG_017013.2:g.21852G>C

ENST00000503591.2:c.1010G>C

ENST00000508793.6:c.1010G>C

ENST00000509690.6:c.614G>C

ENST00000514944.6:c.731G>C

ENST00000604348.6:c.989G>C

ENST00000269305.9:c.1010G>C

ENST00000269305.8:c.1010G>C

ENST00000359597.8:c.993+2836G>C

ENST00000413465.6:c.782+3482G>C

ENST00000420246.6:c.*117G>C

ENST00000445888.6:c.1010G>C

ENST00000455263.6:c.*29G>C

ENST00000504290.5:c.*29G>C

ENST00000504937.5:c.614G>C

ENST00000510385.5:c.*117G>C

ENST00000576024.1:c.54-1009G>C

ENST00000610292.4:c.893G>C

ENST00000610538.4:c.*29G>C

ENST00000610623.4:c.*29G>C

ENST00000615910.4:c.977G>C

ENST00000617185.4:c.*117G>C

ENST00000618944.4:c.*117G>C

ENST00000619186.4:c.533G>C

ENST00000619485.4:c.893G>C

ENST00000620739.4:c.893G>C

ENST00000622645.4:c.*117G>C

ENST00000635293.1:c.893G>C

NM_000546.5:c.1010G>C

NM_001126112.2:c.1010G>C

NM_001126113.2:c.*29G>C
NM_001126114.2:c.*117G>C
NM_001126115.1:c.614G>C
NM_001126116.1:c.*117G>C
NM_001126117.1:c.*29G>C
NM_001126118.1:c.893G>C
NM_001276695.1:c.*29G>C
NM_001276696.1:c.*117G>C
NM_001276697.1:c.533G>C
NM_001276698.1:c.*117G>C
NM_001276699.1:c.*29G>C
NM_001276760.1:c.893G>C
NM_001276761.1:c.893G>C
NM_001276695.2:c.*29G>C
NM_001276696.2:c.*117G>C
NM_001276697.2:c.533G>C
NM_001276698.2:c.*117G>C
NM_001276699.2:c.*29G>C
NM_001276760.2:c.893G>C
NM_001276761.2:c.893G>C
NM_001126112.3:c.1010G>C
NM_001126113.3:c.*29G>C
NM_001126114.3:c.*117G>C
NM_001126115.2:c.614G>C
NM_001126116.2:c.*117G>C
NM_001126117.2:c.*29G>C
NM_001126118.2:c.893G>C
NM_001276695.3:c.*29G>C
NM_001276696.3:c.*117G>C
NM_001276697.3:c.533G>C
NM_001276698.3:c.*117G>C
NM_001276699.3:c.*29G>C
NM_001276760.3:c.893G>C
NM_001276761.3:c.893G>C

Likely Pathogenic

Met criteria codes 6

- PP3
- PM5_Supporting
- PM1_Supporting
- PS2_Supporting
- PM2_Supporting
- PS3

Not Met criteria codes 7

- PP1
- PP4
- BS2
- BS4
- BS3
- BP4
- PS4

Evidence Links 0

Expert Panel

TP53 VCEP

Criteria Specification Information

- [Criteria Specification:](#) ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0
- [Criteria Specification Approval History](#)
- [Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

TP53 VCEP

The NM_000546.6(TP53):c.1010G>C variant in TP53 is a missense variant predicted to cause substitution of arginine by proline at amino acid 337 (p.Arg337Pro). This variant received a total of 0.5 points across 1 proband and therefore PS4 cannot be applied (PS4 not met; PMID: 25584008). This variant has been identified as a de novo occurrence with unconfirmed parental relationships in an individual with a moderately LFS-associated cancer totaling 1 phenotype point (PS2_Supporting; Internal contributor). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965). This variant has 3 somatic occurrences for the same amino acid change in cancerhotspots.org (v2) sufficient to be defined as a mutational hotspot by the Clingen TP53 VCEP (2-9 somatic occurrences, PMID: 30311369) (PM1_Supporting). Computational predictor scores (BayesDel = 0.407328, Align GVGD = Class C25) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of > 15), evidence that correlates with impact to TP53 via protein change (PP3). Another missense variant (p.Arg337Leu) in the same codon have been classified as likely pathogenic for Li-Fraumeni syndrome by the ClinGen TP53 VCEP’s specifications.(PM5_Supporting). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PS3, PP3, PS2_Supporting, PM1_Supporting, PM2_Supporting, PM5_Supporting. (Bayesian Points: 9; VCEP specifications version 2.3)

Met criteria codes

PP3			Computational predictor scores (BayesDel = 0.407328, Align GVGD = Class C25) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of > 15), evidence that correlates with impact to TP53 via protein change (PP3).
PM5_Supporting			Another missense variant (p.Arg337Leu) in the same codon have been classified as likely pathogenic for Li-Fraumeni syndrome by the ClinGen TP53 VCEP’s specifications.(PM5_Supporting).
PM1_Supporting			This variant has 3 somatic occurrences for the same amino acid change in cancerhotspots.org (v2) sufficient to be defined as a mutational hotspot by the Clingen TP53 VCEP (2-9 somatic occurrences, PMID: 30311369) (PM1_Supporting).
PS2_Supporting			This variant has been identified as a de novo occurrence with unconfirmed parental relationships in an individual with a moderately LFS-associated cancer totaling 1 phenotype point (PS2_Supporting; Internal contributor).
PM2_Supporting			This variant has an allele frequency of 0.000002681 (4/1491942 alleles) across gnomAD v4.1.0 which is lower than the Clingen TP53 VCEP threshold (<0.00003) for PM2_Supporting and has a subpopulation allele frequency of <0.00004 in all non-bottleneck populations with 2 or more alleles present (PM2_Supporting).
PS3			In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965).

Not Met criteria codes

PP1			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP4			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

BS2			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS4			This variant received a total of 0.5 points across 1 proband and therefore PS4 cannot be applied (PS4 not met; PMID: 25584008).

Curation History 		
▼ ▼		
Showing 1 to 1 of 1 rows		

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.